Last reviewed · How we verify
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D (COBRA)
The underlying hypothesis is that vedolizumab will modify immune cell trafficking in type 1 diabetes, and that this will be enhanced by pre-treatment with etanercept. This study will determine whether there is mechanistic evidence in support of this hypothesis and provide preliminary information about safety, efficacy, and tolerability of vedolizumab with and without pretreatment with etanercept in adults with type 1 diabetes (T1D)
Details
| Lead sponsor | Benaroya Research Institute |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | Wed Sep 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Jan 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Type 1 Diabetes
Interventions
- Etanercept
- Vedolizumab
Countries
United States